Algernon Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGNPF research report →
Companyalgernonpharmaceuticals.com
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia.
- CEO
- Christopher J. Moreau
- IPO
- 2016
- Employees
- 5
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $997.64K
- P/E
- -0.08
- P/S
- 0.00
- P/B
- 0.06
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -92.73%
- ROIC
- -77.80%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,715,892 · -241.13%
- EPS
- $-0.58 · -131.87%
- Op Income
- $-1,716,631
- FCF YoY
- 58.61%
Performance & Tape
- 52W High
- $0.72
- 52W Low
- $0.04
- 50D MA
- $0.33
- 200D MA
- $0.45
- Beta
- 0.90
- Avg Volume
- 532
Get TickerSpark's AI analysis on AGNPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AGNPF Coverage
We haven't published any research on AGNPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AGNPF Report →